Congratulations to Digital RESI January Innovator’s Pitch Challenge Winners!

14 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireOur 3-day Digital Redefining Early-Stage Investments (RESI) January Conference came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovator’s Pitch Challenge (IPC). Each participating finalist company had a dedicated page featuring a short pitch, executive summary, and other supplementary materials available for viewing.

The Digital RESI January Live Agenda is open to registered attendees until February 13, so there’s still time to check out the Digital RESI January Live Agenda for virtual exhibit of innovative technologies across all life science & healthcare sectors!

The RESI Team would like to thank every IPC company for their virtual presentations, and the hard work to promote their technologies to our RESI community. The Top 3 winners will be awarded with free tickets to future RESI conferences. Congratulations to the Top 3 winners, and thanks to all for voting!

First Place: Concarlo Holdings

Concarlo Holdings, LLC is a precision medicine company focusing on unmet needs in oncology: developing therapeutics and diagnostics to extend the lives of cancer patients, beginning with women with metastatic breast cancer.

Check Concarlo Holdings’ Dedicated Page

 

Tied for Second Place: BCell Solutions

BCell Solutions, Inc., is a pre-clinical biopharmaceutical company commercializing a family of highly anti-inflammatory, small molecule peptides. Uses include treatment of chronic inflammation, acute/hyper-inflammation, and neuroinflammation. Our lead indication is kidney disease, supported by data from two animal models showing BCS Immunotherapy’s successful reversal of loss of kidney autoregulatory function, a key element of chronic kidney disease and renal failure.

Check BCell Solutions’ Dedicated Page

 

Tied for Second Place: Surgical Innovation Associates

Surgical Innovation Associates (SIA) is a Chicago-based medical device spin-out from Northwestern University with FDA 510(k) clearance, CE Mark, and rapidly growing sales for its first product, DuraSorb™ – a patented absorbable surgical mesh in the $1B+ general and reconstructive surgery market. In only a few months on the market, we have grown sales to >$100k/month at >80% gross profit margin. SIA is led by an industry-experienced management team and supported by a veteran Board of Directors as well as a reputable medical advisory board. Existing investors include ex-CEO’s and CFO’s of publicly traded medical device corporations (Baxter Healthcare, Baxalta, etc.), KOL surgeons from leading universities (Northwestern, NYU, Northshore) and respected angel groups from across the country (Harvard Business School Angels, Gopher Angels, Ann Arbor Angels). We’ve also received $2M of NCI SBIR grants with an opportunity for $4M of follow-on grant funding, providing investors with great leverage. We are now seeking a $10M Series B predominantly to fuel sales growth, with a target closing in Q1 2021.

Check Surgical Innovation Associates’ Dedicated Page

Longevity, Health & Innovation’s Innovator’s Pitch Challenge Finalists

14 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

Hosting live pitch sessions has long been an important element in Life Science Nation (LSN)’s partnering conferences. These sessions help companies get their message out to investors who are a fit for their technology and stage of development. On behalf of conference organizers, LSN and Mary Furlong & Associates, we are pleased to highlight the following ten companies participating in the Innovator’s Pitch Challenge this week:

Longevity, Health & Innovation’s Innovator’s Pitch Challenge Finalists

Please click the logo to learn more about these companies, their teams, products, and technology. To learn more about the conference and Innovator’s Pitch Challenge, visit https://longevityhealthinnovation.com/pitch-challenge/.

The Lost Art of Following Up

14 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Following up with a previous correspondence is an inevitability in the digital age, so when did entrepreneurs start taking a lack of response as the recipient’s lack of interest in their message? While this may be true in some instances, it is not always the case. A timely, thoughtful follow-up strategy is one of the best communication tools any fundraising executive may possess, and it often makes the difference between a meeting and another introduction gone unanswered. Such a powerful skillset deserves its own process, so we’ve broken it down:

  1. Introduction: The first message is the one where you introduce yourself and your company, as well as request a meeting. It’s ok if your target investor does not respond immediately (hence this system). To help them understand your position, it’s important to include the following:
      1. Company tagline (5-6 words explaining who you are and what you do)
      2. Elevator pitch (1-3 sentences describing the company and tech)
      3. Technology differentiation, product innovation, or market position
      4. Raise and milestone information
  2. Follow Up 1 (Product/Tech): Why is your product and technology unique? Is it first-in-class? Best-in-class? This is your opportunity to dive into your company’s differentiated value.
  3. Follow Up 2 (Management/Team): Highlight your management and team. How have your people had a notable impact on the business development. What makes your people special?
  4. Follow Up 3 (One Pager): Condense all the important messages you’ve already shared into a one-page tear sheet for quick and easy reference later. Even if the investor you’ve targeted is not a fit, this will make it easier for them to share your company with another.

(Tear Sheet Sample)

Life Science Nation (LSN) has helped hundreds of early-stage startups within life science and healthcare get their branding and messaging straight in order to connect with investors who are a fit for their product and stage of development. We’ve seen great companies neglect the finer details, like a comprehensive follow-up strategy, and hope this helps you along your journey to funding and beyond!

Introducing the Innovator’s Pitch Challenge Finalists!

7 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireLife Science Nation (LSN)’s Inaugural Healthtech Partnering Week launches next week, which means the Innovator’s Pitch Challenge (IPC) is on! The IPC is an opportunity for early-stage, fundraising CEOs to pitch directly to a panel of judges, who follow up with a live Q&A session.

How does it work? The finalist companies deliver pitching materials, including a comprehensive slide deck, executive summary, and a long form pitch video to be hosted on a dedicated webpage the judges review prior to their live session. Sessions are split up by sectors and are designed to match up companies with investors actively seeking opportunities in their space. During the live session, companies deliver a brief short form pitch, which is then followed by a Q&A period with the judges.

Each event sees an incredible line up of early-stage companies delivering promising tech to advance life science and healthcare. LSN is proud to host this powerful meeting of the minds.

Innovator’s Pitch Challenge Finalists

J.P. Morgan Week Update: The Perfect Venue to Launch LSN Healthtech Partnering Week

7 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

It’s that time of year again! J.P. Morgan’s Annual Healthcare Conference has spawned countless concurrent healthcare conferences taking advantage of the influx of industry professionals eager to network and make deals for nearly forty years. The Redefining Early-Stage Investments (RESI) conference series has been a popular addition for several years, and it seemed the obvious choice when we looked to launch our own Healthtech Partnering Week.

Over the past ten months, as many industries slowed down, Life Science Nation (LSN)’s partnering events have ramped up, delivering an increased number of one-on-one meetings between fundraising early-stage companies and investors. The metrics speak for themselves, as we’ve seen an average of 1400+ meetings take place over three days of digital partnering, proving that digital partnering works with investors pulling the deal-making trigger. The proof-of-concept, preclinical and clinical trial money is flowing.

Learn more about Healthtech Partnering Week and join the 500+ investors.

What’s the difference?

MATCHING LSN’s customized partnering system enables fundraising CEOs, investors, and strategic partners to seek opportunities based on several search criteria, most importantly including product fit and stage of development, helping attendees avoid wasted meetings, which can amount to more than half the meetings booked at standard partnering conferences. LSN’s database of thousands of investors and start-ups provides detailed profiles that help attendees increase their chances of success by matching with the best partners for them.

MESSAGING LSN has interviewed thousands of investors in order to learn what their criteria are for taking a meeting and engaging with an investment prospect. The trends we found have been written into a book (FREE PDF COPY) designed to help the scientist-entrepreneur understand how to get their branding and messaging straight. This starts with a cogent 5–7-word tagline, a lucid 6-7-sentence elevator pitch, and a one-page data sheet that succinctly presents all relevant information a potential investor would need at first glance. Finally, tell your unique story through a two-page executive summary and elaborate on your technology in a 10–12-page pitch deck.

FOLLOW-UP Partnering is an extremely competitive contact sport. You need to get your company and message above the noise. Investors and strategic partners are inundated with meeting requests, and if you do not have a compelling tactical plan to go after and secure meetings, you run the risk of getting only 4-6 meetings, instead of 15-20+. It’s a numbers game – we don’t make the rules, but we know how to play by them.

LSN has developed a 4-step follow-up process. The concept of follow-up stops most early-stage entrepreneurs in their tracks and thus limits their interaction with targeted partners. We walk a fundraising CEO through all these issues and set them on the right path through our content, bootcamps and seminars. Preparing CEOs for partnering success is rarely given enough attention, and LSN is passionate about using its insight to help deal-flow to promising teams and their tech.

Check out more tips on partnering and a tutorial of the LSN system. There’s still time to register for events at Healthtech Partnering Week. Don’t miss out!

Partnering in the Age of AgeTech: What the Longevity Market is Missing

7 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

The Inaugural Longevity, Health & Innovation digital partnering event launches next week! This conference, co-organized by Life Science Nation (LSN) and Mary Furlong & Associates (MFA), is designed to bring early-stage companies and investors together, along with industry leaders, to advance deals in the longevity marketplace in order that seniors live longer, healthier lives.

I spoke with LSN CEO, Dennis Ford and MFA CEO, Dr. Mary Furlong on their partnership and thoughts on the industry, particularly where Longevity, Health & Innovation fills the gap in the early-stage ecosystem. There is still time to sign up and begin meeting with leaders in the field – Learn more at https://longevityhealthinnovation.com/.

Hot Investor Mandate: USA-Based VC Invests in Seed Stage, Consumer-Facing and Enterprise Technologies in Digital Health

7 Jan

An early-stage seed fund focuses on seed stage and sometimes Series A. Typical equity allocations range from $500 – 750 K per company. The firm is open to both leading and co-investing. The firm has been investing from a $50M fund and is currently raising a new fund, from which it expects to make new investments.  The firm is seeking opportunities from across the US with a focus on the Bay Area.

The firm invests across multiple industries including healthcare IT. The firm prefers products that do not require FDA approval. Within healthcare IT, the firm considers both consumer-facing and enterprise solutions that demonstrate customer traction and large market potential.

The firm can work with incomplete management teams and would require a board seat on a case-by-case basis. The firm has funded companies in which the founders were either current students or recent graduates from top US universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →

%d bloggers like this: